arrow
V

Vincenzo Libri

university college london
H指数:41
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses

第三次暴露于COVID-19感染或疫苗接种对T细胞反应产生差异化影响

2025-08-210
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy

每周一次艾塞那肽在多系统萎缩患者治疗中的应用

2025-07-290
OAAI
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
LANCET
IF88.5
2024-03-011
OAAI
SARS-CoV-2 mucosal neutralising immunity after vaccination
2024-01-013
OAAI
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
2023-07-0113
OAAI
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study-A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Com-COV2研究中异源COVID疫苗接种计划中免疫反应的持久性-一项纳入mRNA,病毒载体和蛋白质佐剂疫苗的单盲,随机试验

2023-06-017
OAAI
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease
2023-05-2918
OAAI
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

SARS-CoV-2自扩增RNA疫苗的COVAC1 2a期扩大安全性和免疫原性研究

2023-02-0118
OAAI
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

接种间隔对同源与异源新型冠状病毒肺炎疫苗接种程序的反应原性、免疫应答峰值及衰减的影响:Com-COV随机对照试验的探索性分析

2022-11-0126
OAAI
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

BNT162b2和mRNA-1273新型冠状病毒肺炎疫苗在两剂ChAdOx1 nCoV-19或BNT162b2和第三剂BNT162b2 (cov-boost) 后作为第四剂加强剂的安全性,免疫原性和反应原性: 多中心,盲法,2期随机试验

2022-08-01114
OAAI
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

在英国,在两剂ChAdOx1 nCov-19或BNT162b2之后,作为第三剂加强剂给予七种新型冠状病毒肺炎疫苗后的免疫原性持久性: cov-boost试验的三个月分析

2022-06-0147
OAAI
Three-dose vaccination elicits neutralising antibodies against omicron
LANCET
IF88.5
2022-02-0170
OAAI
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

抗新型冠状病毒肺炎自我扩增RNA疫苗的安全性和免疫原性: COVAC1,I期剂量范围试验

2022-02-0194
OAAI
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

在英国 (Com-COV2),掺入mRNA,病毒载体和蛋白质佐剂疫苗的异源新型冠状病毒肺炎初次疫苗接种的免疫原性,安全性和反应原性: 一项单盲,随机,2期,非劣效性试验

LANCET
IF88.5
2022-01-01169
OAAI
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

腺病毒载体和mRNA新型冠状病毒肺炎疫苗 (com-cov) 的异源与同源初免方案的安全性和免疫原性: 一项单盲,随机,非劣效性试验

LANCET
IF88.5
2021-09-01374
OAAI
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
LANCET
IF88.5
2021-07-0196
OAAI
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
LANCET
IF88.5
2021-06-01398
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

ChAdOx1 nCoV-19 (AZD1222) 疫苗对SARS-CoV-2相关变异202012/01 (B.1.1.7) 的疗效: 一项随机对照试验的探索性分析

LANCET
IF88.5
2021-04-01410
OAAI